| Objective This study by testing in breast cancer tissue and TRIM24 expression in the tissue adjacent to breast cancer, and triple motif 24 (TRIM24) protein the gene on chromosome 7 q34, triple motif protein in breast cancer occurrence and development of 24 (TRIM24) and its possible are closely linked.Through experimental analysis in breast cancer tissues triple motif 24 (TRIM24) protein expression level and clinical pathological characteristics of relevance. Preliminary interpretation TRIM24 the role of genes in breast cancer occurrence and development, to further explore in triple motif protein 24 relations with various molecular classification of breast cancer.Methods This study through the two-step immunohistochemistry in breast cancer tissue and normal tissue adjacent to breast carcinoma tissue (100 cases, all the object of study for women; pathological types:infiltrating ductal carcinoma:in 100 cases; lymph node metastasis, axillary lymph node transfer:57 cases, axillary lymph node transfer did not exist:43 cases; pathologic stage:class ? patients:14 cases of class ? patient:47 cases, level ? patient:39 cases; age:patients less than 50 years old:46 cases, greater than or equal to 50 patients:54 cases, tumor size, tumor patients less than or equal to 2 cm in diameter:41 cases,3-5 cm in diameter of the tumor:45 cases of patients with tumor diameter greater than 5 cm:14 cases; clinical stage:?+? positive 67 cases,8 negative,?+? positive 18 cases, negative in 7 cases; Oestrogen receptor:55 cases, negative 45 cases; Progesterone receptor:positive 57 cases, negative 43 patients; Molecular classification:Luminal A:17 were positive, negative 37 cases; 10 cases of Luminal B:9 cases of positive and negative; Its ehrs-2 expression:positive in 11 cases, 4 cases were negative. Basal-like:9 cases of positive and negative 10 cases; P53:60 cases with positive and the negative TRIM24 40 cases) gene expression level determination, analysis TRIM24 expression level in breast cancer and normal tissue adjacent to carcinoma, and to analyze its with patients with pathological type, lymph node metastasis, pathologic stage, age, tumor size, clinical stage,? progesterone receptor (PR)?estrogen receptor (ER)?molecular phenotype:? P53 and so on.Results TRIM24 genes mainly expressed in the cell nucleus. And in breast cancer tissue and normal tissue adjacent to breast cancer nuclei are can see TRIM24 protein positive expression, but TRIM24 gene expression in breast cancer cells were significantly higher than the normal tissue adjacent to breast cancer (X2=18.095, P= 0.001). But 70 cases of breast cancer tissue increased,70.0%(70/100), lower expression, or lack of expression of 30 patients (30/100,30.0%); High expression of normal tissue adjacent to breast cancer cases in 38 cases (38/100,38.0%), low express or express missing cases,62 cases of,62.0%(62/100). In 100 cases of breast cancer tissues, TRIM24 positive expression rate was 70.0%(70/100), significantly higher than the 38.0% of its tissue adjacent to carcinoma of expression rate (38/100, P<0.05)?42 cases with lymph node metastasis is high TRIM24 expression,73.7%(42/57), lower expression or express missing 15,26.3%(15/57); Without lymph node metastasis is TRIM24 high expression of 32 cases (32/43,74.4%), missing or lower expression of 11 cases (11/43,25.6%), (x2=0.071, P=0.071).Pathology classification grade ? TRIM24 high expression in 14 cases (10/14,71.4%), missing or lower expression of 4 cases,29.6%(4/14); Pathology classification class ? cases TRIM24 high expression in 38 cases,81.0%(38/47), lower expression or express missing 9 cases (9/47,19.0%); Pathology classification level ? TRIM24 high expression in 39 cases,56.4%(22/39), lower expression or expression of 17 cases of missing,43.6%(17/39), (x2= 6.632, P= 6.632). Age< TRIM24 high expression in 50 patients with 15 cases,32.6%(15/46), lower expression or express missing 31 cases (31/46,67.4%); Age TRIM24 high expression in 50 cases (19 cases) or higher,35.2%(19/54), lower expression or express missing,64.8%(34/54),34 cases (x2= 0.267, P= 0.267). Tumor diameter less than 2 cm high TRIM24 express,43.9%(18/41) in 18 cases,23 cases of missing or lower expression of,56.1%(23/41); Tumor diameter in TRIM24 high expression of 2-5 cm in 19 cases (19/45,31.1%), missing or lower expression of 26 cases of,69.9%(26/45) of cases, the tumor diameter greater than 5 cm high TRIM24 express cases in 5 cases (5/14,35.7%), missing or lower expression of 9 cases (9/14,64.3%) (x2=0.164, P= 0.164). TRIM24 clinical stage ??+? positie cases,167 cases of high expression,89.3%(67/75), lower expression or lack of expression of 8 cases of,10.3% (8/75); Clinical stage ?+? TRIM24 high expression in 18 cases (18/25,72.0%), low express or express missing,28.0%(7/25),7 cases (x2=0.086, P=0.086).TRIM24 high expression of estrogen receptor positie cases in 16 cases (16/55,29.0%), missing or lower expression of 39 cases (39/55,71.0%); Estrogen receptor negatie TRIM24 high expression of 20 cases,72.4%(20/45), lower expression or express missing 25 cases (25/45,55.6%), (x2=6.012, P=6.012).. TRIM24 high expression of progesterone receptor positie cases,35.1%(20/57),20 patients with low expression or lack of 37 cases,64.7% (37/57); Progesterone receptor negatie TRIM24 high expression in 18 cases (18/43,41.9%), missing or lower expression of 25 cases (25/43,58.1%), (x2= 4.210, P= 0.035). The number of high expression of TRIM24 was 17(17/54,31.5%) and the low level expression or absent was 37 cases(37/54,68.5%)in group of Luminal A, The number of high expression of TRIM24 was 17(9/19,47.4%) and the low level expression or absent was 10 cases (10/19,52.6%) in group of Luminal B. The number of high expression of TRIM24 was 45(11/15,73.3%) and tmissing or lower expression of 4 cases (4/15,26.7%) in group of HER-2 overexpression, The number of high expression of TRIM24 was 8(8/12,66.7%) and the low level expression or absent was 4 cases(4/12,33.3%)in group of Basal-like overexpressionhowever,(x2=8.132,P=0.018). TP53 positive TRIM24 high expression of 45 cases,75.0% (45/60), lower expression or express missing 15,25.0%(15/60); P53 receptor negatie TRIM24 high expression in 30 cases (30/40,75.0%),10 cases of missing or lower expression of,25.0%(10/40), (x2= 1.732, P=1.732).Data show:TRIM24 in breast cancer and the expression of tissue adjacent to carcinoma and estrogen receptor (ER) status) and progesterone receptor (PR) status, pathological classification and molecular classification parameters such as the difference was statistically significant (P<0.05), and the patient age and breast cancer, whether lymph node metastasis, tumor size, clinical stage and P53 difference parameters, andsosignificance (P>0.05)Conclusion Triple motif 24 (TRIM24) protein gene mainly expressed in the cell nucleus, TRIM24 in breast cancer tissue and normal tissue adjacent to breast cancer has different degree of expression, but TRIM24 genes in breast cancer group was significantly higher in normal tissue adjacent to breast cancer. Occurrence and development of breast cancer may be associated with TRIM24 expression intensity increases. TRIM24 gene expression and state of estrogen receptor (ER) and progesterone receptor (PR) status and correlated with pathological grading, molecular classification. TRIM24 expression and breast cancer patients with lymph node metastasis, clinical stage, age, tumor size and P53, no significant correlation (P>0.05). Testing for TRIM24 expression in breast cancer, the important tumor markers may become the judgment of breast cancer. |
PDF Full Text Request